|
Gene: ATP5MC1 |
Gene summary for ATP5MC1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ATP5MC1 | Gene ID | 516 |
Gene name | ATP synthase membrane subunit c locus 1 | |
Gene Alias | ATP5A | |
Cytomap | 17q21.32 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | P05496 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
516 | ATP5MC1 | GSM4909281 | Human | Breast | IDC | 5.71e-12 | 4.63e-01 | 0.21 |
516 | ATP5MC1 | GSM4909282 | Human | Breast | IDC | 4.05e-09 | 4.53e-01 | -0.0288 |
516 | ATP5MC1 | GSM4909285 | Human | Breast | IDC | 2.93e-24 | 5.34e-01 | 0.21 |
516 | ATP5MC1 | GSM4909286 | Human | Breast | IDC | 1.37e-37 | 6.97e-01 | 0.1081 |
516 | ATP5MC1 | GSM4909287 | Human | Breast | IDC | 6.18e-19 | 5.63e-01 | 0.2057 |
516 | ATP5MC1 | GSM4909288 | Human | Breast | IDC | 1.05e-05 | 3.89e-01 | 0.0988 |
516 | ATP5MC1 | GSM4909293 | Human | Breast | IDC | 1.67e-09 | 1.94e-01 | 0.1581 |
516 | ATP5MC1 | GSM4909294 | Human | Breast | IDC | 3.36e-04 | 4.32e-01 | 0.2022 |
516 | ATP5MC1 | GSM4909295 | Human | Breast | IDC | 5.77e-03 | 2.57e-01 | 0.0898 |
516 | ATP5MC1 | GSM4909297 | Human | Breast | IDC | 6.82e-06 | -3.91e-02 | 0.1517 |
516 | ATP5MC1 | GSM4909298 | Human | Breast | IDC | 9.36e-18 | 5.14e-01 | 0.1551 |
516 | ATP5MC1 | GSM4909300 | Human | Breast | IDC | 2.82e-03 | 3.31e-01 | 0.0334 |
516 | ATP5MC1 | GSM4909301 | Human | Breast | IDC | 2.21e-02 | 3.51e-01 | 0.1577 |
516 | ATP5MC1 | GSM4909302 | Human | Breast | IDC | 1.23e-04 | 2.53e-01 | 0.1545 |
516 | ATP5MC1 | GSM4909303 | Human | Breast | IDC | 2.19e-03 | 3.55e-01 | 0.0438 |
516 | ATP5MC1 | GSM4909304 | Human | Breast | IDC | 8.64e-03 | 2.24e-01 | 0.1636 |
516 | ATP5MC1 | GSM4909305 | Human | Breast | IDC | 4.04e-08 | 2.90e-01 | 0.0436 |
516 | ATP5MC1 | GSM4909306 | Human | Breast | IDC | 2.44e-04 | 3.73e-01 | 0.1564 |
516 | ATP5MC1 | GSM4909307 | Human | Breast | IDC | 2.44e-21 | 6.56e-01 | 0.1569 |
516 | ATP5MC1 | GSM4909308 | Human | Breast | IDC | 4.07e-30 | 6.11e-01 | 0.158 |
Page: 1 2 3 4 5 6 7 8 9 10 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00091422 | Colorectum | MSS | nucleoside triphosphate biosynthetic process | 31/3467 | 85/18723 | 7.07e-05 | 1.21e-03 | 31 |
GO:00092012 | Colorectum | MSS | ribonucleoside triphosphate biosynthetic process | 28/3467 | 74/18723 | 7.38e-05 | 1.23e-03 | 28 |
GO:19012932 | Colorectum | MSS | nucleoside phosphate biosynthetic process | 71/3467 | 256/18723 | 1.80e-04 | 2.56e-03 | 71 |
GO:00091652 | Colorectum | MSS | nucleotide biosynthetic process | 70/3467 | 254/18723 | 2.44e-04 | 3.34e-03 | 70 |
GO:00460344 | Colorectum | FAP | ATP metabolic process | 87/2622 | 277/18723 | 6.50e-14 | 6.63e-11 | 87 |
GO:00091504 | Colorectum | FAP | purine ribonucleotide metabolic process | 96/2622 | 368/18723 | 4.91e-10 | 1.20e-07 | 96 |
GO:00061634 | Colorectum | FAP | purine nucleotide metabolic process | 100/2622 | 396/18723 | 1.45e-09 | 2.77e-07 | 100 |
GO:00092593 | Colorectum | FAP | ribonucleotide metabolic process | 97/2622 | 385/18723 | 2.90e-09 | 5.07e-07 | 97 |
GO:00725214 | Colorectum | FAP | purine-containing compound metabolic process | 101/2622 | 416/18723 | 1.11e-08 | 1.33e-06 | 101 |
GO:00196933 | Colorectum | FAP | ribose phosphate metabolic process | 97/2622 | 396/18723 | 1.35e-08 | 1.51e-06 | 97 |
GO:00091174 | Colorectum | FAP | nucleotide metabolic process | 105/2622 | 489/18723 | 3.52e-06 | 1.25e-04 | 105 |
GO:00067534 | Colorectum | FAP | nucleoside phosphate metabolic process | 105/2622 | 497/18723 | 7.47e-06 | 2.25e-04 | 105 |
GO:00091523 | Colorectum | FAP | purine ribonucleotide biosynthetic process | 42/2622 | 169/18723 | 1.17e-04 | 1.91e-03 | 42 |
GO:00091444 | Colorectum | FAP | purine nucleoside triphosphate metabolic process | 26/2622 | 88/18723 | 1.21e-04 | 1.98e-03 | 26 |
GO:00067543 | Colorectum | FAP | ATP biosynthetic process | 19/2622 | 57/18723 | 1.73e-04 | 2.58e-03 | 19 |
GO:19026004 | Colorectum | FAP | proton transmembrane transport | 39/2622 | 157/18723 | 2.03e-04 | 2.92e-03 | 39 |
GO:00092053 | Colorectum | FAP | purine ribonucleoside triphosphate metabolic process | 24/2622 | 82/18723 | 2.55e-04 | 3.51e-03 | 24 |
GO:00092603 | Colorectum | FAP | ribonucleotide biosynthetic process | 43/2622 | 182/18723 | 3.23e-04 | 4.15e-03 | 43 |
GO:00091993 | Colorectum | FAP | ribonucleoside triphosphate metabolic process | 25/2622 | 89/18723 | 3.85e-04 | 4.74e-03 | 25 |
GO:00061643 | Colorectum | FAP | purine nucleotide biosynthetic process | 44/2622 | 191/18723 | 4.96e-04 | 5.71e-03 | 44 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0502016 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
hsa0501616 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
hsa0019016 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
hsa0501016 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
hsa0501416 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0520818 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
hsa0471418 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
hsa0541518 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0502017 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
hsa0501617 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
hsa0019017 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
hsa0501017 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
hsa0501417 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0520819 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
hsa0471419 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
hsa0541519 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |